NEUROPATHIC PAIN SECTION Review Article NMDA Receptor Antagonists for the Treatment of Neuropathic Pain

Objective. The N-methyl-D-Aspartate (NMDA) receptor has been proposed as a primary target for the treatment of neuropathic pain. The aim of the present study was to perform a meta-analysis evalu- ating the effects of (individual) NMDA receptor antagonists on neuropathic pain, and the response (sensitivity) of individual neuropathic pain disorders to NMDA receptor antagonist therapy. Design. PubMed (including MEDLINE), EMBASE and CENTRAL were searched up to October 26, 2009 for randomized placebo controlled trials (RCTs) on neuropathic pain. The methodological quality of the included trials was independently assessed by two authors using the Delphi list. Fixed or random effects model were used to calculate the summary effect size using Hedges' g. Setting. NA. Patients. The patients used for the study were neu- ropathic pain patients. Interventions. The interventions used were NMDA receptor antagonists. Outcome measurements. The outcome of measure- ments was the reduction of spontaneous pain. Results. Twenty-eight studies were included, meeting the inclusion criteria. Summary effect sizes were calculated for subgroups of studies evaluating ketamine IV in complex regional pain syndrome (CRPS), oral memantine in postherptic neuralgia and, respectively, ketamine IV, and oral memantine in pos- tamputation pain. Treatment with ketamine signifi- cantly reduced pain in postamputation pain (pooled summary effect size: -1.18 (confidence interval (CI) 95% -1.98, -0.37), P = 0.004). No significant effect on pain reduction could be established for ketamine IV in CRPS (-0.65 (CI 95% -1.47, 0.16), P = 0.11) oral memantine in postherptic neuralgia (0.03 (CI 95% -0.51, 0.56), P = 0.92) and for oral memantine in pos- tamputation pain (0.38 (CI 95% -0.21, 0.98), P = 0.21). Conclusions. Based on this systematic review, no conclusions can yet be made about the efficacy of NMDA receptor antagonists on neuropathic pain. Additional RCTs in homogenous groups of pain patients are needed to explore the therapeutic potential of NMDA receptor antagonists in neuro- pathic pain.

[1]  Julio Sánchez-Meca,et al.  Weighting by Inverse Variance or by Sample Size in Random-Effects Meta-Analysis , 2010 .

[2]  Erin R. Reichenberger,et al.  Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study , 2009, PAIN®.

[3]  L. Knudsen,et al.  Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine , 2009, PAIN.

[4]  J. Durlak.  How to select, calculate, and interpret effect sizes. , 2009, Journal of pediatric psychology.

[5]  J. Marinus,et al.  Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1 , 2009, PAIN.

[6]  R. Treede,et al.  The Kyoto protocol of IASP Basic Pain Terminology , 2008, PAIN®.

[7]  L. Arendt-Nielsen,et al.  Chronic Phantom Limb Pain: The Effects of Calcitonin, Ketamine, and Their Combination on Pain and Sensory Thresholds , 2008, Anesthesia and analgesia.

[8]  Julio Sánchez-Meca,et al.  Confidence intervals for the overall effect size in random-effects meta-analysis. , 2008, Psychological methods.

[9]  Lan-Fang Zhou,et al.  Small fiber degeneration in post-stroke complex regional pain syndrome I , 2007, Neurology.

[10]  T. Forst,et al.  Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain. , 2007, British journal of clinical pharmacology.

[11]  W. Childers,et al.  N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief. , 2007, Journal of medicinal chemistry.

[12]  P. Paoletti,et al.  NMDA receptor subunits: function and pharmacology. , 2007, Current opinion in pharmacology.

[13]  E. Nisenbaum,et al.  Glutamate receptors and pain. , 2006, Seminars in cell & developmental biology.

[14]  C. Yiannoutsos,et al.  A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy , 2006, Journal of NeuroVirology.

[15]  S. Lipton,et al.  The chemical biology of clinically tolerated NMDA receptor antagonists , 2006, Journal of neurochemistry.

[16]  Tania B. Huedo-Medina,et al.  Assessing heterogeneity in meta-analysis: Q statistic or I2 index? , 2006, Psychological methods.

[17]  Carol Lefebvre,et al.  How to identify randomized controlled trials in MEDLINE: ten years on. , 2006, Journal of the Medical Library Association : JMLA.

[18]  T. Jensen,et al.  Differential Effect of Ketamine and Lidocaine on Spontaneous and Mechanical Evoked Pain in Patients with Nerve Injury Pain , 2006, Anesthesiology.

[19]  Ralf Baron,et al.  Mechanisms of Disease: neuropathic pain—a clinical perspective , 2006, Nature Clinical Practice Neurology.

[20]  Yuchiao Chang,et al.  Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy) , 2006, Pain.

[21]  M. Paré,et al.  Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. , 2006 .

[22]  H. Schaible,et al.  Pathophysiology of pain , 2004, Langenbeck's archives of surgery (Print).

[23]  K. C. Carlsson,et al.  Analgesic effect of dextromethorphan in neuropathic pain , 2004, Acta anaesthesiologica Scandinavica.

[24]  C. Braun,et al.  A Placebo-Controlled Randomized Crossover Trial of the N-Methyl-d-Aspartic Acid Receptor Antagonist, Memantine, in Patients with Chronic Phantom Limb Pain , 2004, Anesthesia and analgesia.

[25]  Hiroshi Baba,et al.  The Role of N-Methyl-d-Aspartate (NMDA) Receptors in Pain: A Review , 2003, Anesthesia and analgesia.

[26]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[27]  P. Schwenkreis,et al.  Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain – results of a randomized double-blinded, placebo-controlled trial , 2003, Pain.

[28]  P. Dayer,et al.  Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. , 2003, Arthritis and rheumatism.

[29]  R. B. Abraham,et al.  Dextromethorphan Mitigates Phantom Pain in Cancer Amputees , 2003, Annals of Surgical Oncology.

[30]  C. Vierck,et al.  Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome , 2003, Pain.

[31]  A. Stubhaug,et al.  Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-d-aspartate (NMDA) receptor antagonist ketamine – a double-blind, cross-over comparison with alfentanil and placebo , 2003, Pain.

[32]  N. Sturrock,et al.  A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[33]  M. Rowbotham,et al.  A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain , 2002, Neurology.

[34]  P. Sedgwick,et al.  Efficacy of intravenous magnesium in neuropathic pain. , 2002, British journal of anaesthesia.

[35]  S. Dohi,et al.  Short- and long-term efficacy of oral ketamine in eight chronic-pain patients , 2002, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[36]  R. B. Abraham,et al.  Dextromethorphan for Phantom Pain Attenuation in Cancer Amputees: A Double-Blind Crossover Trial Involving Three Patients , 2002, The Clinical journal of pain.

[37]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[38]  M. Max,et al.  Dextromethorphan and Memantine in Painful Diabetic Neuropathy and Postherpetic Neuralgia: Efficacy and Dose-Response Trials , 2002, Anesthesiology.

[39]  D. Yarnitsky,et al.  Simultaneous recording of late and ultra-late pain evoked potentials in fibromyalgia , 2001, Clinical Neurophysiology.

[40]  R. Schwartzman,et al.  Neuropathic central pain: epidemiology, etiology, and treatment options. , 2001, Archives of neurology.

[41]  A. Rice,et al.  Mechanisms of neuropathic pain. , 2001, British journal of anaesthesia.

[42]  T. Yaksh,et al.  Concentration–effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain , 2001, Pain.

[43]  M. Rowbotham,et al.  Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions , 2000, Neurology.

[44]  M. Max,et al.  A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias , 2000, Neurology.

[45]  T. Jensen,et al.  Memantine (a N-Methyl-d-Aspartate Receptor Antagonist) in the Treatment of Neuropathic Pain After Amputation or Surgery: A Randomized, Double-Blinded, Cross-Over Study , 2000, Anesthesia and analgesia.

[46]  L. Arendt-Nielsen,et al.  Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients , 2000, Pain.

[47]  E. Eisenberg,et al.  Intravenous lidocaine, amantadine, and placebo in the treatment of sciatica: a double-blind, randomized, controlled study. , 1999, Regional anesthesia and pain medicine.

[48]  A. Dickenson,et al.  NMDA receptors and pain--hopes for novel analgesics. , 1999, Regional anesthesia and pain medicine.

[49]  H. Vet,et al.  The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. , 1998, Journal of clinical epidemiology.

[50]  D. Yarnitsky,et al.  The NMDA (N‐methyl‐D‐aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: A double‐blind, placebo‐controlled study , 1998, European journal of pain.

[51]  B. Galer,et al.  Pain assessment and evaluation of patients who have neuropathic pain. , 1998, Neurologic clinics.

[52]  Julio Sánchez-Meca,et al.  Weighting by Inverse Variance or by Sample Size in Meta-Analysis: A Simulation Study , 1998 .

[53]  D. Yarnitsky,et al.  The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial , 1998, Pain.

[54]  L Arendt-Nielsen,et al.  Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. , 1996, British journal of anaesthesia.

[55]  L. Arendt-Nielsen,et al.  The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input , 1996, PAIN.

[56]  L. Arendt-Nielsen,et al.  NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride , 1996, Pain.

[57]  L. Hedges,et al.  The Handbook of Research Synthesis , 1995 .

[58]  R. Coggeshall,et al.  Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin , 1995, Neuroscience Letters.

[59]  M. Byas-Smith,et al.  Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. , 1995, Clinical neuropharmacology.

[60]  R. Hanka.  The Handbook of Research Synthesis , 1994 .

[61]  Alec B. O’Connor.  Neuropathic Pain , 2012, PharmacoEconomics.

[62]  H C W de Vet,et al.  Ergonomic and physiotherapeutic interventions for treating work-related complaints of the arm, neck or shoulder in adults. , 2006, The Cochrane database of systematic reviews.

[63]  N. B. Finnerupa,et al.  Algorithm for neuropathic pain treatment: An evidence based proposal , 2005 .

[64]  G. Bennett.  Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. , 2000, Journal of pain and symptom management.